257 related articles for article (PubMed ID: 10636461)
1. Inactivation of factor Xa by the synthetic inhibitor DX-9065a causes strong anticoagulant and antiplatelet actions in human blood.
Kaiser B; Jeske W; Walenga JM; Fareed J
Blood Coagul Fibrinolysis; 1999 Dec; 10(8):495-501. PubMed ID: 10636461
[TBL] [Abstract][Full Text] [Related]
2. Global anticoagulant effects of a synthetic anti-factor Xa inhibitor (DX-9065a): implications for interventional use.
Tobu M; Iqbal O; Ma Q; Schultz C; Jeske W; Hoppensteadt D; Lewis B; Fareed D; Fareed J
Clin Appl Thromb Hemost; 2003 Jan; 9(1):1-17. PubMed ID: 12643318
[TBL] [Abstract][Full Text] [Related]
3. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants.
Morishima Y; Tanabe K; Terada Y; Hara T; Kunitada S
Thromb Haemost; 1997 Nov; 78(5):1366-71. PubMed ID: 9408021
[TBL] [Abstract][Full Text] [Related]
4. Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor.
Hara T; Yokoyama A; Morishima Y; Kunitada S
Thromb Res; 1995 Oct; 80(1):99-104. PubMed ID: 8578544
[TBL] [Abstract][Full Text] [Related]
5. Synthetic selective inhibitors of coagulation factor Xa strongly inhibit thrombin generation without affecting initial thrombin forming time necessary for platelet activation in hemostasis.
Ieko M; Tarumi T; Takeda M; Naito S; Nakabayashi T; Koike T
J Thromb Haemost; 2004 Apr; 2(4):612-8. PubMed ID: 15102016
[TBL] [Abstract][Full Text] [Related]
6. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa.
Hara T; Yokoyama A; Ishihara H; Yokoyama Y; Nagahara T; Iwamoto M
Thromb Haemost; 1994 Mar; 71(3):314-9. PubMed ID: 8029795
[TBL] [Abstract][Full Text] [Related]
7. Effects of a factor Xa inhibitor, DX-9065a, in a novel rabbit model of venous thrombosis.
Rogers KL; Chi L; Rapundalo ST; Kramer JB; Gallagher KP
Basic Res Cardiol; 1999 Feb; 94(1):15-22. PubMed ID: 10097826
[TBL] [Abstract][Full Text] [Related]
8. Effect of the novel direct factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease.
Becker RC; Alexander JH; Dyke C; Huang Y; Saint-Jacques H; Hasselblad V; Harrington RA; Bovill EG;
Thromb Res; 2006; 117(4):439-46. PubMed ID: 15882894
[TBL] [Abstract][Full Text] [Related]
9. Effects of a synthetic factor Xa inhibitor (JTV-803) on various laboratory tests.
Tobu M; Iqbal O; Hoppensteadt DA; Shultz C; Jeske W; Fareed J
Clin Appl Thromb Hemost; 2002 Oct; 8(4):325-36. PubMed ID: 12516682
[TBL] [Abstract][Full Text] [Related]
10. Photodecarboxylation of DX-9065a, a new factor Xa inhibitor, in aqueous solution.
Kawai Y; Matsubayashi K
Chem Pharm Bull (Tokyo); 1998 Jan; 46(1):131-5. PubMed ID: 9468645
[TBL] [Abstract][Full Text] [Related]
11. Effects of DX-9065a, an inhibitor of factor Xa, on ellagic acid-induced plantar skin thrombosis assessed in tetrodotoxin- and N(omega)-nitro-L-arginine-treated rats.
Chino D; Fujita Y; Ishii K; Nakayama K
J Pharmacol Sci; 2003 Apr; 91(4):319-29. PubMed ID: 12719661
[TBL] [Abstract][Full Text] [Related]
12. A specific inhibitor of factor Xa, DX-9065a, exerts effective protection against experimental tumor induced disseminated intravascular coagulation in rats.
Tanabe K; Terada Y; Shibutani T; Kunitada S; Kondo T
Thromb Res; 1999 Oct; 96(2):135-43. PubMed ID: 10574591
[TBL] [Abstract][Full Text] [Related]
13. Dibasic (amidinoaryl)propanoic acid derivatives as novel blood coagulation factor Xa inhibitors.
Nagahara T; Yokoyama Y; Inamura K; Katakura S; Komoriya S; Yamaguchi H; Hara T; Iwamoto M
J Med Chem; 1994 Apr; 37(8):1200-7. PubMed ID: 8164262
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of proposed modes of binding of (2S)-2-[4-[[(3S)-1-acetimidoyl-3-pyrrolidinyl]oxy]phenyl]-3-(7-am idino- 2- naphthyl)propanoic acid hydrochloride and some analogs to factor Xa using a comparative molecular field analysis.
Vaz RJ; McLean LR; Pelton JT
J Comput Aided Mol Des; 1998 Mar; 12(2):99-110. PubMed ID: 9690170
[TBL] [Abstract][Full Text] [Related]
15. DX 9065A a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies.
Herbert JM; Bernat A; Dol F; Hérault JP; Crépon B; Lormeau JC
J Pharmacol Exp Ther; 1996 Mar; 276(3):1030-8. PubMed ID: 8786532
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological activity of amidinobicyclic compounds (derivatives of DX-9065a) as factor Xa inhibitors: SAR study of S1 and aryl binding sites.
Komoriya S; Kanaya N; Nagahara T; Yokoyama A; Inamura K; Yokoyama Y; Katakura S; Hara T
Bioorg Med Chem; 2004 May; 12(9):2099-114. PubMed ID: 15080912
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of DX-9065a, argatroban, and synthetic pentasaccharide on tissue thromboplastin inhibition test and dilute Russell's viper venom test.
Gerbutavicius R; Iqbal O; Messmore HL; Wehrmacher WH; Hoppensteadt DA; Gerbutaviciene R; Griniute R; Fareed J
Clin Appl Thromb Hemost; 2003 Oct; 9(4):317-23. PubMed ID: 14653441
[TBL] [Abstract][Full Text] [Related]
18. DX-9065a inhibition of factor Xa and the prothrombinase complex: mechanism of inhibition and comparison with therapeutic heparins.
Rezaie AR
Thromb Haemost; 2003 Jan; 89(1):112-21. PubMed ID: 12540961
[TBL] [Abstract][Full Text] [Related]
19. Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a.
Graff J; Picard-Willems B; Harder S
Int J Clin Pharmacol Ther; 2007 Apr; 45(4):237-43. PubMed ID: 17474542
[TBL] [Abstract][Full Text] [Related]
20. First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation.
Dyke CK; Becker RC; Kleiman NS; Hochman JS; Bovill EG; Lincoff AM; Gerstenblith G; Dzavik V; Gardner LH; Hasselblad V; Zillman LA; Shimoto Y; Robertson TL; Kunitada S; Armstrong PW; Harrington RA
Circulation; 2002 May; 105(20):2385-91. PubMed ID: 12021225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
